CA2961004A1 - Recovery of aspartyl (asparaginyl) beta hydroxylase (haah) from an exosomal fraction of human sera from cancer patients - Google Patents

Recovery of aspartyl (asparaginyl) beta hydroxylase (haah) from an exosomal fraction of human sera from cancer patients Download PDF

Info

Publication number
CA2961004A1
CA2961004A1 CA2961004A CA2961004A CA2961004A1 CA 2961004 A1 CA2961004 A1 CA 2961004A1 CA 2961004 A CA2961004 A CA 2961004A CA 2961004 A CA2961004 A CA 2961004A CA 2961004 A1 CA2961004 A1 CA 2961004A1
Authority
CA
Canada
Prior art keywords
haah
exosomes
serum
elisa
recovery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2961004A
Other languages
English (en)
French (fr)
Inventor
Mark Semenuk
Hossein Ghanbari
Michael Lebowitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Panacea Pharmaceuticals Inc
Original Assignee
Panacea Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Pharmaceuticals Inc filed Critical Panacea Pharmaceuticals Inc
Publication of CA2961004A1 publication Critical patent/CA2961004A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G01N33/57585—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G01N33/5759—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90245—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2961004A 2014-09-12 2015-09-14 Recovery of aspartyl (asparaginyl) beta hydroxylase (haah) from an exosomal fraction of human sera from cancer patients Abandoned CA2961004A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462049582P 2014-09-12 2014-09-12
US62/049,582 2014-09-12
PCT/US2015/049976 WO2016040941A1 (en) 2014-09-12 2015-09-14 Recovery of aspartyl (asparaginyl) beta hydroxylase (haah) from an exosomal fraction of human sera from cancer patients

Publications (1)

Publication Number Publication Date
CA2961004A1 true CA2961004A1 (en) 2016-03-17

Family

ID=55454511

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2961004A Abandoned CA2961004A1 (en) 2014-09-12 2015-09-14 Recovery of aspartyl (asparaginyl) beta hydroxylase (haah) from an exosomal fraction of human sera from cancer patients

Country Status (5)

Country Link
US (2) US20160077098A1 (enExample)
EP (1) EP3191841A4 (enExample)
JP (1) JP6669731B2 (enExample)
CA (1) CA2961004A1 (enExample)
WO (1) WO2016040941A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019032742A1 (en) * 2017-08-11 2019-02-14 Panacea Pharmaceticals Inc. HAAH AND MMP-9 AS COMPLEMENTARY CANCER BIOMARKERS AND METASTASE PREDICTORS WHEN COMBINING THEM
CN107907689A (zh) * 2017-10-10 2018-04-13 北京大学 外泌体蛋白cd5l的检测方法
CN111269986A (zh) * 2020-03-24 2020-06-12 江西惠肽生物科技有限公司 外泌体中asph基因在肺癌早期诊断试剂盒中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835370B2 (en) * 1999-11-08 2004-12-28 Rhode Island Hospital Diagnosis and treatment of malignant neoplasms
US20080124718A1 (en) * 2006-01-27 2008-05-29 Panacea Pharmaceuticals, Inc. Methods of diagnosing, predicting therapeutic efficacy and screening for new therapeutic agents for leukemia
US20090298097A1 (en) * 2007-07-17 2009-12-03 Harris Pamela J Methods for the diagnosis of lung cancer
US20130178383A1 (en) * 2008-11-12 2013-07-11 David Spetzler Vesicle isolation methods
EP2730662A1 (en) * 2008-11-12 2014-05-14 Caris Life Sciences Luxembourg Holdings Methods and systems of using exosomes for determining phenotypes
US9128101B2 (en) * 2010-03-01 2015-09-08 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
WO2012115885A1 (en) * 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers
KR20140136805A (ko) * 2013-05-21 2014-12-01 건국대학교 산학협력단 신규한 인간 엑소좀 단백질 및 그 용도

Also Published As

Publication number Publication date
US20210148915A9 (en) 2021-05-20
WO2016040941A1 (en) 2016-03-17
JP6669731B2 (ja) 2020-03-18
EP3191841A1 (en) 2017-07-19
EP3191841A4 (en) 2018-03-14
JP2017526931A (ja) 2017-09-14
US20160077098A1 (en) 2016-03-17
US20180203013A1 (en) 2018-07-19

Similar Documents

Publication Publication Date Title
Gao et al. A novel strategy for facile serum exosome isolation based on specific interactions between phospholipid bilayers and TiO 2
US20160370265A1 (en) Method for isolating exosomes
US11079374B2 (en) Methods and kits for exosome isolation and quantification
Li et al. Noninvasive Diagnosis and Molecular Phenotyping of Breast Cancer through Microbead‐Assisted Flow Cytometry Detection of Tumor‐Derived Extracellular Vesicles
JP6381033B2 (ja) 前立腺癌と前立腺肥大を識別するための方法およびキット
US9146231B2 (en) Method for testing vascular endothelial damage and testing kit
Yang et al. Bead‐Based Extracellular Vesicle Analysis Using Flow Cytometry
CN110873711B (zh) 一种基于全自动化学发光分析仪的血清tk1检测试剂盒
WO2024001044A1 (zh) 一种与肺癌相关的生物标志物组合、含其的试剂盒及其用途
WO2010101047A1 (ja) 子宮内膜症の判定方法、および子宮内膜症の診断用キット
EP2950099A1 (en) Pretreatment method for sample for detecting hbs antigen, and use therefor
US20210148915A9 (en) Recovery of aspartyl (asparaginyl) beta hydroxylase (haah) from an exosomal fraction of human sera from cancer patients
Bok et al. Exosomes isolation from bovine serum: qualitative and quantitative comparison between ultracentrifugation, combination ultracentrifugation and size exclusion chromatography, and exoEasy methods
US20220162272A1 (en) Compositions and methods of determining a level of infection in a subject
CN102313813B (zh) 从生物体液样本中富集与检测稀有细胞的整合方法
JP7449530B2 (ja) 腎癌の検出方法及び検査薬
CN110967489B (zh) 可溶性cd146作为血脑屏障损伤标志物在中枢神经系统疾病中的应用
US20220276231A1 (en) Method for measuring beta-1,3-1,6-glucan
JP2015169608A (ja) 癌の検査方法
CN119064595B (zh) 蛋白标记物在识别急性肺栓塞并发肺动脉高压模型中的应用
JP6760562B2 (ja) 卵巣明細胞癌患者の予後を予測するための情報提供方法
KR102739746B1 (ko) 바르토넬라 헨셀라이 유래 세포외 소포체를 이용한 바르토넬라 감염증 진단 방법
NL2030266B1 (en) Combination kit and method for predicting childhood asthma attack
CN108139400A (zh) 确定血液样本或抽吸样本中上皮细胞浓度的方法
WO2023006790A1 (en) Method for the detection of organ derived extracellular vesicles

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200909

FZDE Discontinued

Effective date: 20230124

FZDE Discontinued

Effective date: 20230124